May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
A new keratitis rat model for evaluation of anti–Acanthamoeba polyphaga agents
Author Affiliations & Notes
  • C.A. Vasseneix
    Ophtalmologie,
    Laboratoire de Parasitologie,
    CHU Charles Nicolle, Rouen, France
  • G. Gargala
    Laboratoire de Parasitologie,
    CHU Charles Nicolle, Rouen, France
  • M. Muraine
    Ophtalmologie,
    CHU Charles Nicolle, Rouen, France
  • J.–J. Ballet
    Laboratoire d'Immunologie et Immunopathologie, CHU Clemenceau, Caen, France
  • L. Favennec
    Laboratoire de Parasitologie,
    CHU Charles Nicolle, Rouen, France
  • G. Brasseur
    Ophtalmologie,
    CHU Charles Nicolle, Rouen, France
  • Footnotes
    Commercial Relationships  C.A. Vasseneix, None; G. Gargala, None; M. Muraine, None; J. Ballet, None; L. Favennec, None; G. Brasseur, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4963. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.A. Vasseneix, G. Gargala, M. Muraine, J.–J. Ballet, L. Favennec, G. Brasseur; A new keratitis rat model for evaluation of anti–Acanthamoeba polyphaga agents . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4963.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Free–living Acanthamoeba sp. are a cause of potentially devastating human keratitis. Current lack of non–empirical, validated therapies and frequent sequellae prompt the development of experimental models suitable for evaluation of candidate anti–amoebal agents. The aim of this work was to obtain a rat model of chronic amoebic keratitis suitable for screening candidate therapeutic agents with documented anti–acanthamoebal activity in vitro. Methods: Sprague–Dawley rats were infected by intracorneal inoculation of 103 or 104 axenic Acanthamoeba polyphaga trophozoites associated with local corticosteroids. Controls consisted of non–infected steroid–treated or untreated rats. Corneal morphology was examined weekly and, 35 days after inoculation, animals were killed and local infection assessed by corneal microbiological and histocytological examination. In vivo and in vitro anti–amoebal activities of miltefosine were evaluated using this model and axenic cultures, and compared with those of the established anti–amoebal agents polyhexamethylene biguanide (PHMB) and hexamidine di–isethionate tested alone or in combination. Results: Size of inoculum and corticosteroid dose were found key factor for the maintenance of a chronic infection which was best obtained with 104 Acanthamoeba polyphaga combined with a weekly subconjunctival injection of betamethasone (0.28mg) (p<0.05). In vivo, combination of PHMB and hexamidine diisethionate resulted in corneal healing twelve days after inoculation and was more effective than miltefosine, PHMB and hexamidine diisethionate alone. In vitro, miltefosine was found active (MIC: 27.4 µmol), while PHMB (MIC: 14.6 µM) and hexamidine diisethionate (MIC: 555µm) exhibited a synergistic effect (FIC: 0.006). Conclusions: The present chronic rat model of Acanthamoeba polyphaga keratitis was found suitable for pharmacological studies of candidate agents.

Keywords: Acanthamoeba • keratitis • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×